Issue 38

Renewed Energy: How Biopharma is Driving Progress Despite Financial Headwinds

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Navigating Industry Challenges with Renewed Optimism

So far, 2025 has been financially challenging for the biopharmaceutical and biotech sectors — with limited access to capital and lean financing on offer — further complicated by macroeconomic uncertainty (1). However, despite these obstacles, stakeholders from biopharma and biotech have been voicing optimism about innovation that can help to drive forward success and ensure patients gain access to life-saving therapies.

Read more here.

FEATURED STORIES

Investment Limiting Effect of the Capability Gap

Watch here.

A Rapid Evolution: Highlights and Insights from Advancing Complex Biologics Day 2025

Read more here.

Bend Adds Particle Engineering and Spray-Drying Capabilities with New Suites

Read more here.

Nanoform Receives Funding to Advance Clinical Development of Nanoapalutamide

Read more here.

Enzene Expands New Jersey Facility to Boost Next-Gen Biomanufacturing

Read more here.

CSL Gains FDA Approval for its Preventative HAE Treatment

Read more here.